{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:33:27Z","timestamp":1790289207366,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ijantimicag.2016.09.027","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T07:46:57Z","timestamp":1479196017000},"page":"62-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Piperacillin\/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study"],"prefix":"10.1016","volume":"49","author":[{"given":"H\u00e9l\u00e8ne","family":"Guet-Revillet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-9257","authenticated-orcid":false,"given":"Elise","family":"Tomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Emirian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Join-Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"L\u00e9cuyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Ralph","family":"Zahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1179\/1973947813Y.0000000121","article-title":"Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009\u20132011)","volume":"26","author":"Sader","year":"2014","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1473-3099(14)70950-8","article-title":"\u03b2-Lactam and \u03b2-lactamase inhibitor combinations in the treatment of extended-spectrum \u03b2-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?","volume":"15","author":"Harris","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0025","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0030","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin\u2013tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0035","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.48.12.4718-4724.2004","article-title":"Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation","volume":"48","author":"Lodise","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0040","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin\u2013tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0045","author":"Comit\u00e9 de l'Antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0050","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0055","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jac\/dki243","article-title":"Population pharmacokinetics and pharmacodynamics of piperacillin\/tazobactam in patients with complicated intra-abdominal infection","volume":"56","author":"Li","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0060","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1128\/AAC.00937-12","article-title":"Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile","volume":"56","author":"Landersdorfer","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0065","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0924-8579(02)00105-X","article-title":"Correlation between pharmacokinetic\/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection","volume":"19","author":"Frimodt-M\u00f8ller","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0070","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1128\/AAC.00521-12","article-title":"Population pharmacokinetics of extended-infusion piperacillin\u2013tazobactam in hospitalized patients with nosocomial infections","volume":"56","author":"Felton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0075","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1093\/ndt\/gfr810","article-title":"Acute pyelonephritis in adults: a case series of 223 patients","volume":"27","author":"Rollino","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1471-2369-12-68","article-title":"The clinical and imaging presentation of acute \u2018non complicated\u2019 pyelonephritis: a new profile for an ancient disease","volume":"12","author":"Piccoli","year":"2011","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0085","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/cid\/cis857","article-title":"Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin\/tazobactam: a systematic review and meta-analysis","volume":"56","author":"Falagas","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0090","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/jac\/dkt300","article-title":"Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin\/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations","volume":"69","author":"Butterfield","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0095","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.00135-13","article-title":"Impact of the MIC of piperacillin\u2013tazobactam on the outcome of patients with bacteremia due to extended-spectrum-\u03b2-lactamase-producing Escherichia coli","volume":"57","author":"Retamar","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0100","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00381-05","article-title":"Clinical correlation of the CLSI susceptibility breakpoint for piperacillin\u2013tazobactam against extended-spectrum-\u03b2-lactamase-producing Escherichia coli and Klebsiella species","volume":"50","author":"Gavin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13756-015-0055-6","article-title":"Comparable outcomes for \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae","volume":"4","author":"Harris","year":"2015","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0110","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00365-16","article-title":"A multinational, preregistered cohort study of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"60","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153696","article-title":"Empiric piperacillin\u2013tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"11","author":"Ng","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0120","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/jac\/dkt450","article-title":"Determining a clinical framework for use of cefepime and \u03b2-lactam\/\u03b2-lactamase inhibitors in the treatment of infections caused by extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"69","author":"Nguyen","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0125","first-page":"45","article-title":"The inoculum effect of antibiotics against CTX-M-extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"13","author":"Wu","year":"2014","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0130","doi-asserted-by":"crossref","DOI":"10.1111\/1469-0691.12677","article-title":"In vitro and in vivo activities of piperacillin\u2013tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae","volume":"20","author":"Harada","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0135","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.medmal.2013.01.006","article-title":"Alternatives to carbapenems in ESBL-producing Escherichia coli infections","volume":"43","author":"Fournier","year":"2013","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0140","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1128\/AAC.35.6.1219","article-title":"Effect of \u03b2-lactamase inhibitors on the activities of various \u03b2-lactam agents against anaerobic bacteria","volume":"35","author":"Wexler","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.09.027_bib0145","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1128\/AAC.00891-10","article-title":"Effect of antibiotic treatment on establishment and elimination of intestinal colonization by KPC-producing Klebsiella pneumoniae in mice","volume":"55","author":"Perez","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791630334X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791630334X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T15:02:41Z","timestamp":1749740561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485791630334X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S092485791630334X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.09.027","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Piperacillin\/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}